Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of ...

Dupilumab use in children appears to be tied to a higher incidence of inflammatory eye conditions, including conjunctivitis ...

Dupilumab shows significant benefits in prurigo nodularis severity and healing outcomes. Learn more about the latest Phase III trial findings.

BOSTON -- Add-on dupilumab (Dupixent) significantly reduced itching and urticaria in patients with chronic spontaneous urticaria (CSU) whose symptoms were uncontrolled with H1-antihistamine therapy.

In this exclusive MedPage Today video, Thomas B. Casale, MD, of the University of South Florida in Tampa, discusses new analyses from the LIBERTY-CUPID studies evaluating dupilumab (Dupixent) in ...

Please provide your email address to receive an email when new articles are posted on . Individuals received 8-week omalizumab followed by either 24-week dupilumab or placebo. The groups significantly ...

Dupilumab treatment led to significant SCORAD score reductions, with 37% achieving a 75% reduction and 72% reaching mild disease status by week 16. Improvements were observed as early as week 2, with ...

These improvements — as measured by a significantly lower annualized rate of acute exacerbations, significantly better lung function and quality of life, and significantly less severe symptoms than ...

Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug — dupilumab — that showed rapid and sustained improvements in patients in a pivotal Phase 3 ...

VANCOUVER, Canada — New evidence from the phase 3 EoE KIDS trial supports the safety and efficacy of dupilumab (Dupixent) treatment for children aged 1-11 years with eosinophilic esophagitis (EoE).